Gene therapy cuts brain damage in two diseases
A protein involved in cellular transport turns out to limit serious brain damage in mice. And it works across two distinct neurological diseases.
TDP-43 is a protein that normally sits in the cell nucleus and helps process genetic information. In a range of brain diseases, including ALS and a form of dementia called frontotemporal dementia, TDP-43 accumulates outside the nucleus. These clumps disrupt how brain cells function and eventually cause them to die. There is currently no effective treatment.
Caveolin-1 as a protective protein
Earlier research had already shown that increasing the production of caveolin-1 in the brain reduces Alzheimer’s-related damage in mouse models. Caveolin-1 is involved in regulating small indentations in the cell membrane called caveolae, which play a role in cell signaling and waste clearance. Now the researchers applied the same approach to a mouse model with elevated TDP-43 levels.
Mice that received the gene therapy showed fewer TDP-43 aggregates, less loss of brain cells, and better performance on behavioral tests. The therapy worked by using a virus to deliver caveolin-1 into brain cells, which then produce more of the protein themselves.
Broad applicability as a promising signal
The fact that the same therapy works in two different disease models is meaningful. It suggests that caveolin-1 activates a general protective mechanism rather than a disease-specific pathway. That makes it potentially relevant for a broader group of brain diseases associated with the buildup of misfolded proteins, a phenomenon that becomes more common as we age.
The results are still limited to mouse studies. The path to clinical applications in humans is long. But the findings give researchers a concrete reason to explore caveolin-1 further as a target for neuroprotective therapies.